Having trouble accessing articles? Reset your cache.

Dapagliflozin: Phase III data

A double-blind Phase III trial in 814 patients with Type II diabetes inadequately controlled with metformin showed that dapagliflozin plus metformin met the primary endpoint of non-inferiority to glipizide plus metformin

Read the full 313 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE